The Relationship Between Plasma Gelsolin Levels and Myeloperoxidase in Patients Undergoing Hemodialysis: A Prospective, Observational, Controlled Study
1Department of Biochemistry, Erciyes University Faculty of Medicine, Kayseri, Türkiye; Department of Medical Biochemistry, Erciyes University Institute of Health Sciences, Kayseri, Türkiye
2Department of Biochemistry, Erciyes University Faculty of Medicine, Kayseri, Türkiye
3Department of Midwifery, Nigde Omer Halisdemir University, Faculty of Health Sciences, Nigde, Türkiye
4Division of Nephrology, Department of Internal Medicine, Erciyes University Faculty of Medicine, Kayseri, Türkiye
J Clin Pract Res 2024; 46(1): 41-46 DOI: 10.14744/cpr.2024.83703
Full Text PDF


Objective: Given the association of inflammatory conditions with the development of comorbidities, particularly cardiovascular diseases, it is crucial to monitor inflammation in hemodialysis patients. This study aimed to evaluate plasma gelsolin and myeloperoxidase (MPO) levels before and after dialysis sessions and to assess their relationship with inflammation.
Materials and Methods: The study included 16 healthy volunteers and 30 patients receiving regular hemodialysis treatment. Along with routine biochemical analyses, plasma gelsolin and MPO levels were measured in blood samples taken from the study group before and after the sessions.
Results: Plasma gelsolin levels were found to be statistically higher both before and after dialysis compared to the control group (p=0.000); however, there was no significant change during the session (p=0.094). Conversely, plasma MPO activity, which was significantly higher before dialysis, increased at the end of the session (p=0.000).
Conclusion: It can be concluded that elevated levels of gelsolin are associated with a chronic inflammatory response, as indicated by high-sensitivity C-reactive protein (hs-CRP) and MPO levels. Consequently, gelsolin could be considered a supportive treatment strategy for these patients.